Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04580992
Other study ID # APA Brugada study
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date November 16, 2020
Est. completion date October 31, 2022

Study information

Verified date September 2021
Source Universitair Ziekenhuis Brussel
Contact Evelien Vandeurzen
Phone 024749237
Email evelien.vandeurzen@uzbrussel.be
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Background: Brugada Syndrome is an inherited channelopathy associated with risk of ventricular fibrillation and sudden cardiac death in a structurally normal heart. The diagnosis is based on the characteristic electrocardiographic pattern (coved type STsegment elevation, 2mm followed by a negative T-wave in one or more of the right precordial leads V1 to V2), noted spontaneously or upon administration of a sodiumchannel blocker, such as Ajmaline. The majority of adults screened for Brugada Syndrome, undergo the Ajmaline provocation-test awake. Ajmaline is therefore injected continuously, with incremental steps through an intravenous placed catheter, according to cardiological protocols. In a subpopulation of anxious adults, or when another electrophysiological procedure is required at the same time, sedation or general anaesthesia is provided. Similarly, in the paediatric population, it is common practice to perform the challenge test under sedation. Based on the sodium channel blocking properties of propofol, it is not unthinkable that anaesthetic agents might interact with the pharmacodynamic or pharmacokinetic effects of Ajmaline on the myocardial sodium channels. Existence of such interaction would implicate altered diagnostic value of the Ajmaline-provocation-test for patients that undergo the challenge under general anaesthesia. Objective: The goal of this study is to evaluate if the Ajmaline-provocation-test results in altered electrocardiographic effects when performed under general anaesthesia with propofol. Study-design: A prospective observational study. Study population: Patients are eligible for inclusion if they have been diagnosed with Brugada Syndrome, are American Society of Anaesthesiologists (ASA) 2 - 4, older than 18 years and are scheduled for epicardial ablation. Exclusion criteria are known allergy for propofol, a body mass index (BMI) above 35 for female and 42 for male patients, obstetric patients, critical illness, conditions that exclude continuous propofol infusion due to higher risk for propofol infusion syndrome (PRIS), such as mitochondrial disease, fatty acid oxidation disorder, co-enzyme Q deficiency and any other condition that renders the patient unfit for elective surgery. Intervention: This study is prospective, observational. Main study parameters/endpoints: The primary endpoints are changes in the ST-, Jp-, QRS-, T(p-e)-segments and T(p-e)/QT -ratio changes during steady-state anaesthesia. The secondary endpoint is the occurrence of de novo arrhythmias. Nature and extent of the burden and risks associated with participation: This is an observational study; therefore, the risks associated are no other than those associated with the intervention itself. No additional blood-samples, tests or consults are necessitated during participation; therefore, no extra burden is associated.


Recruitment information / eligibility

Status Recruiting
Enrollment 25
Est. completion date October 31, 2022
Est. primary completion date October 31, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age >= 18 year - ASA 2, 3, 4 - Epicardial ablation indicated by cardiologist - Written informed consent Exclusion Criteria: - A known allergy to propofol - BMI>35 for female patients - BMI > 42 for male patients - Obstetric anaesthesia - Critical Illness - Mitochondrial disease - Fatty acid oxidation disorder - Co-enzyme Q deficiency - Any condition that renders the patient unfit for elective surgery

Study Design


Intervention

Drug:
Ajmaline
Ajmaline administration

Locations

Country Name City State
Belgium UZ Brussels Jette Brussel

Sponsors (1)

Lead Sponsor Collaborator
Universitair Ziekenhuis Brussel

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary ST-, QRS-, Jp-, QT-, QTcB-, QTcFr- and JT-interval Ventricular Arrhythmogenesis during the intervention/procedure/surgery
Secondary Malignant arrhythmias Previously not-known or non-existing ventricular or supraventricular arrhythmias resulting in compromising hemodynamic instability detrimentally affecting cardiac output and requiring advanced cardiac life treatment. intra- or postoperatively (up to 24hours upon discharge from the post anaesthetic care unit)
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Completed NCT05791032 - Sub Chronic Evaluation for ATP With an Extravascular Placed ICD Lead (STEP ICD) Study N/A
Completed NCT04011631 - Evaluation of the iD-SystemTM, One-Handed Disposable Internal Defibrillation System. N/A
Active, not recruiting NCT03700125 - Pre-hospital ECMO in Advanced Resuscitation in Patients With Refractory Cardiac Arrest. ( SUB30 ) N/A
Not yet recruiting NCT05325385 - Ventricular Fibrillation Following Out-of-hospital Cardiac Arrest
Completed NCT00139542 - AED Use in Out-of-Hospital Cardiac Arrest: A New Algorithm Named "One Shock Per Minute" Phase 3
Completed NCT00241800 - Medications and the Risk of Sudden Cardiac Death N/A
Completed NCT00119847 - Electrophysiological Effects of Late PCI After MI N/A
Completed NCT00004560 - Public Access Defibrillation (PAD) Community Trial Phase 3
Completed NCT00000531 - Antiarrhythmics Versus Implantable Defibrillators (AVID) Phase 3
Completed NCT00000502 - Evaluation of SC-V Versus Conventional CPR Phase 3
Completed NCT00000492 - Beta-Blocker Heart Attack Trial (BHAT) Phase 3
Completed NCT04080986 - DOuble SEquential External Defibrillation for Refractory VF N/A
Completed NCT01789554 - The Use of Mobile Phones in Out of Hospital Cardiac Arrest to Increase Bystander CPR N/A
Completed NCT01940081 - The Leiden Nonischemic Cardiomyopathy Study
Completed NCT01089634 - Left Ventricular Capture Management Study
Completed NCT00382928 - Automatic External Defibrillation Monitoring in Cardiac Arrest Phase 1
Completed NCT01161589 - First Arrhythmia Collection of Transvenous and Simultaneous Subcutaneous Implantable Defibrillator Data N/A
Terminated NCT00776087 - European Health Economic Trial on Home Monitoring in ICD and CRT-D Patients (EuroEco) N/A
Recruiting NCT04576130 - A Danish ICD-study in Patients With Coronary Artery Disease Resuscitated From Ventricular Fibrillation N/A